EXACT Sciences (NASDAQ:EXAS) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Several other research analysts have also recently weighed in on the stock. Bank of America boosted their price target on shares of EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a report on Wednesday, November 29th. Canaccord Genuity restated a “buy” rating and set a $45.00 price target on shares of EXACT Sciences in a report on Thursday, September 7th. Leerink Swann restated an “outperform” rating and set a $67.00 price target (up from $63.00) on shares of EXACT Sciences in a report on Monday, November 13th. Robert W. Baird cut shares of EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price target on the stock. in a report on Monday, November 13th. Finally, Jefferies Group boosted their price target on shares of EXACT Sciences to $60.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $50.58.

Shares of EXACT Sciences (NASDAQ EXAS) opened at $53.73 on Thursday. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. EXACT Sciences has a 52-week low of $13.05 and a 52-week high of $63.60.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. During the same period in the previous year, the company earned ($0.36) earnings per share. The firm’s revenue for the quarter was up 158.4% compared to the same quarter last year. equities analysts forecast that EXACT Sciences will post -1.12 earnings per share for the current fiscal year.

In other EXACT Sciences news, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total value of $7,976,391.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP D Scott Coward sold 29,115 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the transaction, the senior vice president now owns 64,991 shares in the company, valued at $3,064,975.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 595,396 shares of company stock worth $32,953,769. Corporate insiders own 4.00% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. boosted its stake in EXACT Sciences by 2,925.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after acquiring an additional 3,072 shares during the last quarter. SG Americas Securities LLC purchased a new position in EXACT Sciences in the third quarter valued at about $183,000. Krilogy Financial LLC boosted its stake in EXACT Sciences by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 3,650 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in EXACT Sciences by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 600 shares during the last quarter. Finally, Crescent Grove Advisors LLC purchased a new position in EXACT Sciences in the third quarter valued at about $200,000. Hedge funds and other institutional investors own 82.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/exact-sciences-exas-upgraded-to-buy-at-bidaskclub/1775420.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.